methyl 5-methyl-7-(thiophen-2-yl)-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate | 537002-57-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: methyl 5-methyl-7-(thiophen-2-yl)-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate
• 英文别名: methyl 5-methyl-7-thiophen-2-yl-1,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate
• CAS: 537002-57-6
• 化学式: C₁₁H₁₁N₅O₂S
• 分子量: 277.307
• InChiKey: DHAAPHKIEVZEHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS DE DIHYDROPYRIDINE, DIHYDROPYRIMIDINE ET DIHYDROPYRANE FACULTATIVEMENT CONDENSÉS AGISSANT COMME BLOQUEURS DES CANAUX CALCIQUES TARDIFS
  申请人：CV THERAPEUTICS INC

  公开号：WO2009006580A1

  公开（公告）日：2009-01-08

  The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
• [EN] OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS DE DIHYDROPYRIDINE, DE DIHYDROPYRIMIDINE ET DE DIHYDROPYRANE FACULTATIVEMENT CONDENSÉS, JOUANT LE RÔLE DE BLOQUEURS TARDIFS DES CANAUX SODIQUES
  申请人：CV THERAPEUTICS INC

  公开号：WO2010002483A1

  公开（公告）日：2010-01-07

  The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Ql, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.